22
Company Overview
7 key markets
Growth marketsMature markets
China
#1Malaysia
#1Indonesia
#1Philippines
#1Singapore
#2India
#2Hong Kong
# Market share
Source: United Nations, Department of Economic and Social Affairs
Incorporated in 2001
The first cord blood bank to be set up in
Singapore and amongst the first in Asia
15 years of cord blood banking
experience as well as a successful track
record of cord blood releases for
transplants and therapeutic applications
Listed in Mainboard of Singapore
Exchange
Presence and facilities in 9 countries
Presence through associate(s) and sub-
licensing partner(s) and marketing
agent(s): Thailand (Thai Stemlife),
Myanmar and China
Our mission:
We are a consumer healthcare company
that serves the needs of the mother and
child. We deliver the highest of quality
standards in service and product offerings.
We maximise all stakeholders’ value by
engaging all employees to enable the
Company to achieve its fullest potential.
Myanmar
Marketing AgentSub-licensing
Partner
Associate
Thailand
33
Company Overview
Collection at birth, processing,
testing, cryopreservation and storage
of stem cells from the umbilical cord
blood – Haematopoietic Stem
Cells (HSCs)
6 products and services offering
Cord Blood Banking
Collection, processing, testing,
cryopreservation and storage of the
umbilical cord lining - Mesenchymal
stem cells (MSCs) and Epithelial
stem cells (EpSCs)
Patented technology – Exclusive licensing from CellResearch Corporation
Umbilical Cord Lining Banking
Catered for newborns, MetaScreen
detects as many as 106 metabolic
disorders
Non-invasive and advanced technology
testing on urine specimens
Metascreen: Non-invasive Urine based Metabolic Screening
Banking Diagnostics
Catered for expectant women in their 1st
trimester
Analyses cell free fetal DNA in mother’s
blood to detect fetal chromosomal
abnormalities using whole genome
sequencing
iGene: Non-Invasive Prenatal Testing (NIPT)
Simple and non-invasive detection of
vision problems in children as early as 6
months to 6 years old, for early
intervention.
Eyescreen: Paediatric Vision Screening
Collection, processing, testing,
cryopreservation and storage of the
umbilical cord tissue (Wharton’s
Jelly) – MSCs
Processed using in-house technique
for cell extraction and expansion.
Umbilical Cord Tissue (Wharton’s Jelly) Banking
44
Singapore Hong Kong India Philippines Indonesia
Top 1 Cordlife HealthBaby LifeCell Cordlife Cordlife
Top 2 StemCord Cordlife CryoBanks StemCord* BabyBanks*
Top 3 -- CryoLife Cordlife Medical City StemCord*
Total # of Companies
2 6 11 5 5
62%
91%
69%
98%
85%
38%
9%
31%
2%
15%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Singapore Hong Kong(China)
India Philippines Indonesia
Top 3* Others
Less concentration in India due to the larger number of companies
Cordlife in market leader banks in 3 markets & amongst top 3 in 2 markets
Source: Deloitte & Touche Financial Advisory Services Limited report,10 April 2013
Top 3 banks represent 62% of market share in each country
Positioned to capture Asian growth
55
Top 3 private cord blood bank
player in each key market
Market share leadership in
each jurisdiction
Strong recurring cashflows
from high penetration rates
in each market
Higher profit margins from
economies of scale
Multiple product offerings
utilizing the same platform
Our Vision
Where
are we
now?
No.1consumer healthcare
player in Asia catering to
the mother & child segment
Our target
Increase penetration
Strategic partnerships
New service offerings
Focus on core competencies
Expand in the region
Unlock network value and synergies
Investments and marketing
efforts necessary to:
66
Cordlife Singapore’s Achievements
AABB
accreditation since
2005
Reaccreditation
audits: 2008 | 2009 |
2011 | 2013 | 2015
Ministry of Health
license
since 2002
Audits:
Once every 2 years
Good Distribution
Practice for
Medical Devices
since 2010
Cordlife subsidiariesCordlife Hong Kong:
• AABB accreditation
• ISO 9001:2008
• RCPA Quality Assurance Program
(participation)
Hong Kong Screening Centre Limited
• The College of American
Pathologists (certification)
Cordlife India:
• AABB accreditation
• ISO 9001:2008
• Drug Controller General India
certification
• The College of American
Pathologists (certfication)
Cordlife Philippines:
• ISO 9001:2008
• Department of Health registration
Cordlife Indonesia:
• ISO 9001:2008
• Ministry of Health certification
(DEPKES)
Stemlife Malaysia
• MOH certification
• ISO 15189
• The College of American
Pathologists (Certification)
FACT NetCord
since 2015
Commitment to Quality
77
Securities Investors
Association (Singapore)
16th SIAS Investors’
Choice Awards – Runner-
Up in Mid and Small
Category – Singapore
Corporate Governance
Award 2015
MyBB
Parent-Child
Favourite Cord
Blood & Umbilical
Cord Bank Co
Forbes Asia
200 Best Under a Billion
Brand name with proven record
Hong Kong
Economic Times
Baby & Kid
Brands Award
Capital Weekly
The Best
Performance
Company Award
Baby-Kingdom
Top 10 Family
Brand Award 2013
Frost & Sullivan
2016 Asian Pacific Stem
Cell Banking Company of
the Year Award
88
Andrew Ekaputra, PhDTechnical Director,
Innovation
Li Ming Ming, PhDDeputy Lab Director,
Group Lab Operations
Dr. Chiew Yoke FongMedical Director
Dr. Jennifer TeoMedical Director
Dr. Arvin C. FaundoCord Blood Bank Director
Dr. Cherie DalyMedical Affairs Consultant
Banking
Tang Kin Fai, PhDDeputy Lab Director,
Group Lab OperationsThet Hnin YiChief Financial Officer
Tan HuiyingGroup Director,
Quality & Ops.
Jamie WoonGroup Director,
Brand Devt. & Innovation
Stella LeeGroup Director,
Org. Devt.
Lin Aigu, PhDDeputy Lab Director,
Group Lab Operations
Scientific & Medical Advisors
Tomiko Kuhara, PhDScientific Advisor
Metabolic screening
Vrushali Joshi, PhDScientific Advisor
Metabolic screening
Corporate Team Members
Dr. Inez WongMedical Advisor
Paediatric Opthalmologist
Daniel Lim, PhDDeputy Technical Director,
Innovation
Dr Wong Chiang Yin
Group Chief
Executive Officer
Tan Poh Lan
Group Chief
Operating Officer
99
Group Structure
Cordlife
(Hong Kong)
100.0%
Shanghai
Cordlife
Biomedical
Research
100.0%
Cordlife Stem
Cell Technology
100.0%
Cordlife
Technologies
100.0%
CS Cell
Technologies
100.0%
SL
Diagnostics
Sdn. Bhd.
100.0%
Stemlife
89.88%
Cordlife Medical
Phils.
99.9%
Hong Kong
Screening Centre
67.0%
Cordlife
Sciences (India)
99.99%
PT. Cordlife
Persada
67.0%
Cordlife Group Limited
Malaysia China Hong Kong Singapore
Hong Kong Philippines India Indonesia
Thai
Stemlife
40.0%
Stemlife Pte.
Ltd.
100.0%
Stemlife
Logistics Sdn.
Bhd.
100.0%
Stemlife
Therapeutics
Sdn. Bhd.
100.0%
Stemlife
Properties
Sdn. Bhd.
100.0%
Thailand Singapore MalaysiaMalaysia Malaysia Malaysia
Singapore
1111
Cord blood banking
Haematopoietic stem cells
• Collection of umbilical cord blood shortly after birth
• Isolation of haematopoietic stem cells: blood forming cells
• Standard therapy for over 80 conditions including certain cancers and blood related disorders such as leukaemia, lymphoma & neuroblastoma
• Potential therapy for many more diseases in clinical trials e.g. autism, cerebral palsy
1212
Cord lining banking
• Storage of umbilical cord epithelium & sub-epithelium• Rich in two stem cell types: Mesenchymal and Epithelial• Tissue repair, regenerative medicine & synergy with cord
blood• Patented technology and source material• Well over 650* clinical trials worldwide• Potential applications for heart attack, stroke, cartilage repair
and spinal cord injury.
*Source: clinicaltrials.gov – search term “umbilical cord”, accessed on 24 Nov 2016
1313
Newborn metabolic screening
• Inborn errors of metabolism (IEMs) are rare genetic disorders in which the body is lacking enzymes that maintain normal bodily metabolic function.
• Timely, non-invasive and accurate detection of more than 100+ Inborn Errors of Metabolism (IEMs) through urine specimen
• First in Cordlife’s pipeline of preventive healthcare services catering to the child
• Available in Hong Kong, Philippines and Indonesia
• Launching soon in Malaysia and Singapore
1414
• A safe and non-invasive paediatric eye screening that does not require any physical contact with the child or the need to deploy eyedrops to dilate the pupils.
• Able to detect up to 11 eye conditions such as Myopia (short-sightedness), and Strabismus (crossed eyes) and Amblyopia (lazy eye) in children as early as 6 months to 6 years old.
• Timely vision screening is recommended as being essential in infancy and childhood for the early detection and treatment of eye problems.
• Available in Singapore
Paediatric vision screening
1515
• Catered for expectant women in their 1st trimester
• Non-invasive prenatal testing (NIPT) is a relatively new type of screening that analysis cell free fetal DNA in mother’s blood to detect fetal chromosomal abnormalities with very high accuracy.
• Cordlife has partnered with iGene Diagnostics, a Singapore based molecular diagnostics company, to offer NIPT.
• Available in Singapore, Philippines and Indonesia.
Non-invasive Prenatal Testing
1818
3-Year Consolidated Statement of
Comprehensive Income(S$’mil) FY2014 FY2015 FY2016
Total revenue 49.1 57.6 59.6
Cost of sales (14.2) (17.6) (20.2)
Gross profit 34.9 40.0 39.5
Gross profit margin 71.1% 69.5% 66.2%
Other operating income 1.3 0.8 1.0
Selling and marketing expenses (12.2) (17.7) (19.0)
Administrative expenses (15.1) (17.3) (19.8)
Finance income 0.3 0.5 1.5
Finance costs (0.2) (0.2) (0.3)
Profit before income tax from
operations9.0 6.1 2.9
Non-core items * 22.8 27.1 10.4
Profit before income tax 31.8 33.2 13.3
Income tax expense (1.5) (1.1) (0.8)
Profit for the financial year 30.3 32.1 12.5
Note :
*Non-core items shown on next slide.
Numbers might not tally due to rounding differences.
1919
(S$’mil) FY2014 FY2015 FY2016
Share of results of associate (2.3) (0.4) (0.1)
Impairment loss on investment in associate - (2.6) -
Fair value gain/(loss) on investment properties 0.1 0.3 (0.2)
Fair value changes on financial asset
designated at fair value through P&L18.7 10.4 4.5
Fair value changes on derivative asset - 12.9 2.5
Gain on transfer from associate to financial
asset designated at fair value through P&L6.3 - -
Exchange differences - 4.7 6.0
Gain on sale of financial asset designated at
fair value through P&L- - 0.2
Gain on sale of convertible note - - 5.0
Remeasurement loss on previously held equity
interest in subsidiary- - (1.6)
Note repurchase expense - - (2.0)
Other expenses - - (2.4)
Finance income - 6.6 3.8
Finance costs - (4.6) (5.3)
Total non-core items 22.8 27.1 10.4
Note : Numbers might not tally due to rounding differences.
3-Year Consolidated Statement of
Comprehensive Income – Non-core
2020
3-Year Statement of Financial Position
(S$’mil) FY2014 FY2015 FY2016
Non-current assets
Investment in associate 16.8 13.5 -
Financial asset designated at fair value
through P&L50.5 60.9 -
Available-for-sale asset - - 4.2
Derivative asset - 38.0 -
Property, plant and equipment 8.4 9.6 13.3
Investment properties 4.8 3.8 9.2
Intangible assets 1.9 2.5 14.7
Deferred tax assets - - 0.2
Trade receivables 46.0 54.6 60.5
Other receivables 0.3 98.5 4.3
Total non-current assets 128.7 281.4 106.4
2121
(S$’mil) FY2014 FY2015 FY2016
Current assets
Cash and cash equivalents 32.6 15.7 69.7
Fixed deposits 11.8 12.3 53.4
Pledged fixed deposits 0.3 0.3 0.3
Short term investments 1.0 1.2 15.0
Trade receivables 12.9 15.3 21.0
Other receivables 1.1 4.2 2.0
Prepayments 1.7 1.7 1.7
Inventories 0.6 0.9 1.1
Total current assets 62.0 51.6 164.2
Current liabilities
Trade and other payables 8.9 11.6 13.5
Insurance contract liabilities - - 1.1
Deferred revenue 5.4 4.0 15.5
Tax payable 1.6 1.1 0.6
Interest-bearing borrowings 4.4 4.5 2.1
Total current liabilities 20.3 21.2 32.8
Net current assets 41.7 30.4 131.4
3-Year Statement of Financial Position
2222
(S$’mil) FY2014 FY2015 FY2016
Non-current liabilities
Other payables 0.1 1.3 0.1
Deferred revenue 20.5 23.6 24.7
Deferred tax liabilities 0.1 0.1 4.1
Interest-bearing borrowings 8.4 7.4 8.7
Notes payable - 117.5 67.4
Total non-current liabilities 29.1 149.9 105.0
Net assets 141.3 161.9 132.8
Capital and reserves
Share capital 96.7 96.7 96.7
Treasury shares (3.9) (9.9) (9.8)
Accumulated profits 51.3 78.6 54.7
Other reserves (2.6) (3.0) (10.8)
141.5 162.4 130.8
Non-controlling interests (0.2) (0.5) 2.0
Total equity 141.3 161.9 132.8
3-Year Statement of Financial Position
2323
3-Year Statement of Cash Flows
As at June 30 (S$’mil) 2014 2015 2016
Net cash flows generated
from/(used in) operating activities
3.7 (3.4) (4.4)
Net cash flows (used in)/from
investing activities
(9.6) (115.1) 153.3
Net cash flows from/(used in)
financing activities
30.6 101.7 (95.1)*
Note :
*Includes dividend paid of S$36.3 million, repurchase of notes of S$52.9 million, repayment of interest-bearing borrowings of
S$1.0 million and interest paid on notes of S$4.9 million.